Dose Ranging Study of Alfuzosin in Patients With Lower Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia

• Status: Completed
• Trial end date: 2005-08-01
• Target enrollment: 0
• Participant gender: Male

Summary

The primary objective is to assess the dose-response relationship of SL77.0499 10 (alfuzosin hydrochloride) 5 mg, 10 mg, 15 mg, and placebo once daily during a 12-week oral administration period for the efficacy in patients with lower urinary tract symptoms (LUTS) related to BPH.

Secondary objectives are to assess the efficacy of each dose of alfuzosin as compared with placebo and to assess the safety of each dose of alfuzosin.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sanofi
• Treatments: Alfuzosin

Criteria

Inclusion Criteria:

• suffering from LUTS related to BPH for at least 6 months;

• having an IPSS >13;

• having a urinary peak flow rate 5.0 to 12.0 mL/s for a voided volume of at least 150 mL;

• having a residual urine volume < or = 200 mL.